KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Aquestive Therapeutics (AQST) Return on Capital Employed (2018 - 2025)

Aquestive Therapeutics has reported Return on Capital Employed over the past 8 years, most recently at 0.62% for Q4 2025.

  • Quarterly results put Return on Capital Employed at 0.62% for Q4 2025, down 27.0% from a year ago — trailing twelve months through Dec 2025 was 0.62% (down 27.0% YoY), and the annual figure for FY2025 was 0.85%, down 34.0%.
  • Return on Capital Employed for Q4 2025 was 0.62% at Aquestive Therapeutics, down from 0.54% in the prior quarter.
  • Over the last five years, Return on Capital Employed for AQST hit a ceiling of 0.14% in Q2 2024 and a floor of 2.82% in Q4 2022.
  • Median Return on Capital Employed over the past 5 years was 0.77% (2021), compared with a mean of 0.96%.
  • Biggest five-year swings in Return on Capital Employed: crashed -199bps in 2022 and later soared 244bps in 2023.
  • Aquestive Therapeutics' Return on Capital Employed stood at 0.83% in 2021, then plummeted by -239bps to 2.82% in 2022, then soared by 87bps to 0.38% in 2023, then grew by 6bps to 0.35% in 2024, then crashed by -75bps to 0.62% in 2025.
  • The last three reported values for Return on Capital Employed were 0.62% (Q4 2025), 0.54% (Q3 2025), and 0.7% (Q2 2025) per Business Quant data.